In 2024, we will celebrate the 75th anniversary since the establishment of our predecessor, Kyowa Hakko Kogyo Co., Ltd. Since our founding, we have continued striving to contribute to the enriched lives and health of many people by delivering chemically and pharmaceutically innovative products uniquely developed through our original ideas. In July 2025, we have decided to make a major transformation in our business structure.
Within the Kirin Group to which we belong, the Health Science business is positioned as a new growth area. We uphold CSV (Creating Shared Value) and place solving social issues and achieving economic value at the core of our management. In this era, companies that walk together with society are chosen by all stakeholders, and this trend will surely accelerate going forward.
As a company addressing social challenges at a global level and providing solutions, we will leverage our long-established fermentation and purification technologies to develop our business. Through the development, production, and supply of specialty materials and pharmaceutical raw materials, we will steadily realize "new value creation." We will continue to propose safe and secure products and services, meeting the trust you place in us.
Please continue to look forward to Kyowa Hakko Bio.
Kyowa Hakko Bio Co., Ltd.
President and CEO: Koji Fukada